Symbols

BAX

Baxter International·NYSE

--(--)

BAX fundamentals

BAX Q4 2025 Earnings

Baxter International (BAX) released its earnings on Feb 12, 2026: revenue was 2.97B (YoY +8.03%), beat estimates; EPS was 0.36 (YoY -37.93%), missed estimates.

Revenue / YoY

2.97B

+8.03%

EPS / YoY

0.36

-37.93%

Report date

Feb 12, 2026

BAX Earnings Call Summary for Q4,2025

Revenue Growth Mixed: Q4 2025 sales up 8% reported/3% operational, but EPS missed due to margin pressure and tax rate hike.
Key Risks: Novum LVP shipment hold ($40M+ annual risk), IV Solutions demand baseline decline, and pharma supply chain challenges.
Strategic Actions: Simplified operating model, $80M tariff mitigation, and $130-140M TSA income in 2026.
2026 Outlook: Flat to +1% sales, 13-14% operating margin, and back-half weighted recovery with Q1 as most challenging quarter.
Cash Flow Focus: Free cash flow improvement in 2026, with $438M in 2025 and $456M in Q4.

Earnings

EPS

Revenue

Revenue & Expenses

BAX has released its 2025 Q4 earnings report, with revenue of 2.97B, reflecting a YoY change of 8.03%, and net profit of -1.13B, showing a YoY change of -121.18%. The Sankey diagram below clearly presents BAX's revenue sources and cost distribution.

Key Indicators

Baxter International (BAX) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Baxter International (BAX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Baxter International (BAX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Baxter International (BAX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown